PapersFlow Research Brief
Hematopoietic Stem Cell Transplantation
Research Guide
What is Hematopoietic Stem Cell Transplantation?
Hematopoietic stem cell transplantation is a therapeutic procedure that replaces diseased or damaged bone marrow with healthy hematopoietic stem cells from a donor to restore normal blood cell production.
The field encompasses 73,860 published works on the biology, regulation, and clinical applications of hematopoietic stem cells within the bone marrow niche. Key areas include HSC quiescence, stem cell aging, graft-versus-host disease, hematologic malignancies, and mesenchymal stem cell support for HSC function. Research also addresses stem cell mobilization and transplantation mechanisms for treating blood disorders.
Topic Hierarchy
Research Sub-Topics
Graft-versus-Host Disease
This sub-topic explores the pathophysiology, clinical staging, diagnosis, and therapeutic management of acute and chronic GVHD post-HSCT. Researchers investigate immune mechanisms, biomarker discovery, and novel immunosuppressive strategies.
Hematopoietic Stem Cell Mobilization
This sub-topic examines the molecular mechanisms, pharmacologic agents, and clinical protocols for mobilizing HSCs from bone marrow into peripheral blood. Researchers study plerixafor, G-CSF kinetics, and poor mobilizer phenotypes.
Bone Marrow Niche Regulation
This sub-topic investigates the cellular and molecular interactions within the HSC niche involving osteoblasts, mesenchymal stromal cells, and endothelial cells. Researchers explore niche-mediated quiescence, self-renewal, and leukemia support.
HSC Quiescence and Self-Renewal
This sub-topic addresses the cell cycle regulation, molecular pathways, and epigenetic control maintaining HSC dormancy and repopulating capacity. Researchers study label-retaining cells, stress responses, and quiescence exit signals.
Mesenchymal Stem Cells in HSCT
This sub-topic covers the immunomodulatory properties, niche-support functions, and clinical applications of MSCs in preventing GVHD and aiding engraftment. Researchers evaluate co-transplantation trials and manufacturing standardization.
Why It Matters
Hematopoietic stem cell transplantation treats hematologic malignancies and advanced aplastic anemia, as demonstrated in studies of 61 patients conditioned with total body irradiation or cyclophosphamide who received HL-A-matched sibling marrow grafts, where clinical manifestations of graft-versus-host disease were systematically documented (Glucksberg et al., 1974, "CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S"). Standardized criteria from NIH consensus reports enable consistent diagnosis and staging of chronic GVHD in clinical trials, improving patient outcomes across thousands of cases (Jagasia et al., 2014, "National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report"; Filipovich et al., 2005, "National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report"). Mesenchymal stem cells modulate allogeneic immune responses, reducing GVHD incidence in bone marrow transplantation (Aggarwal and Pittenger, 2004, "Human mesenchymal stem cells modulate allogeneic immune cell responses"). Osteoblastic cells in the bone marrow niche regulate HSC maintenance, supporting long-term engraftment post-transplant (Calvi et al., 2003, "Osteoblastic cells regulate the haematopoietic stem cell niche").
Reading Guide
Where to Start
"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report" by Jagasia et al. (2014), as it provides foundational clinical criteria for GVHD diagnosis and staging essential for understanding transplantation complications.
Key Papers Explained
Bonnet and Dick (1997, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell") and Lapidot et al. (1994, "A cell initiating human acute myeloid leukaemia after transplantation into SCID mice") establish the hierarchical model of AML from primitive HSCs, informing transplantation targets. Glucksberg et al. (1974, "CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S") documents early GVHD manifestations in 61 patients, which Filipovich et al. (2005, "National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report") and Jagasia et al. (2014, "National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report") refine into standardized trial criteria. Aggarwal and Pittenger (2004, "Human mesenchymal stem cells modulate allogeneic immune cell responses") and Calvi et al. (2003, "Osteoblastic cells regulate the haematopoietic stem cell niche") connect supportive roles of MSCs and niche cells to improve transplantation success.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on HSC quiescence, stem cell aging, and mobilization mechanisms within the bone marrow niche, as reflected in the 73,860 works. No recent preprints or news from the last 12 months indicate steady progress without major shifts.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Human acute myeloid leukemia is organized as a hierarchy that ... | 1997 | Nature Medicine | 6.9K | ✕ |
| 2 | National Institutes of Health Consensus Development Project on... | 2014 | Biology of Blood and M... | 5.2K | ✓ |
| 3 | Targeting Hypoxia-Inducible Factors for the Treatment of Anemi... | 2017 | American Journal of Ne... | 4.8K | ✓ |
| 4 | A cell initiating human acute myeloid leukaemia after transpla... | 1994 | Nature | 4.7K | ✕ |
| 5 | Human mesenchymal stem cells modulate allogeneic immune cell r... | 2004 | Blood | 4.5K | ✓ |
| 6 | CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN ... | 1974 | Transplantation | 3.7K | ✕ |
| 7 | Bone marrow transplant | 1997 | OPAL (Open@LaTrobe) (L... | 3.6K | ✓ |
| 8 | National Institutes of Health Consensus Development Project on... | 2005 | Biology of Blood and M... | 3.5K | ✕ |
| 9 | Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid... | 2011 | New England Journal of... | 3.5K | ✓ |
| 10 | Osteoblastic cells regulate the haematopoietic stem cell niche | 2003 | Nature | 3.4K | ✓ |
Frequently Asked Questions
What criteria define chronic graft-versus-host disease in transplantation trials?
The 2014 NIH Consensus refines 2005 criteria for diagnosing and staging chronic GVHD, maintaining the framework while incorporating new evidence for clinical trials (Jagasia et al., 2014, "National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report"). The 2005 report established initial standardized diagnostic and staging systems (Filipovich et al., 2005, "National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report"). These enable consistent severity scoring across patients.
How do mesenchymal stem cells affect immune responses in transplantation?
Human mesenchymal stem cells modulate allogeneic immune cell responses, evading immune clearance and reducing graft-versus-host disease incidence in bone marrow recipients (Aggarwal and Pittenger, 2004, "Human mesenchymal stem cells modulate allogeneic immune cell responses"). Transplanted MSCs persist long-term without rejection. They support HSC function in the bone marrow niche.
What is the hierarchical organization of human acute myeloid leukemia in transplantation contexts?
Human acute myeloid leukemia originates from a hierarchy driven by primitive hematopoietic cells, as shown by leukemia-initiating cells identified in patients (Bonnet and Dick, 1997, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell"). A single cell from a leukemia patient initiated AML in SCID mice post-transplantation, confirming its leukemogenic potential (Lapidot et al., 1994, "A cell initiating human acute myeloid leukaemia after transplantation into SCID mice"). This informs targeted therapies in HSC transplantation.
What role do osteoblastic cells play in the hematopoietic stem cell niche?
Osteoblastic cells regulate the hematopoietic stem cell niche, influencing HSC maintenance and function in bone marrow (Calvi et al., 2003, "Osteoblastic cells regulate the haematopoietic stem cell niche"). They provide essential signals for HSC quiescence and self-renewal. This regulation is critical for successful engraftment in transplantation.
What are the clinical manifestations of graft-versus-host disease after marrow transplantation?
In 61 patients receiving HL-A-matched sibling marrow for aplastic anemia or malignancies, GVHD manifested in skin, liver, and gut, graded by severity after conditioning with irradiation or cyclophosphamide (Glucksberg et al., 1974, "CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S"). Manifestations varied by organ involvement and timing post-transplant. Standardized grading aids prognosis and management.
Open Research Questions
- ? How can the bone marrow niche be optimized to enhance HSC quiescence and long-term engraftment post-transplantation?
- ? What mechanisms drive stem cell aging and its impact on transplantation outcomes in older patients?
- ? How do mesenchymal stem cells precisely modulate immune responses to minimize graft-versus-host disease without impairing graft-versus-leukemia effects?
- ? What factors determine the hierarchy of leukemia-initiating cells in AML and their resistance to transplantation-based therapies?
- ? How do osteoblastic cells interact with other niche components to regulate HSC mobilization and homing during transplantation?
Recent Trends
The field maintains 73,860 works with no specified 5-year growth rate.
Established criteria for chronic GVHD from Jagasia et al. build on Filipovich et al. (2005), reflecting ongoing refinement in clinical standards without new preprints or news in the last 12 months.
2014Research Hematopoietic Stem Cell Transplantation with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hematopoietic Stem Cell Transplantation with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers